阿普唑仑预处理与惊恐障碍患者对35%二氧化碳的易感性
Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
作者信息
Pols H, Verburg K, Hauzer R, Meijer J, Griez E
机构信息
Department of Psychiatry & Neuropsychology, State University of Limburg, Maastricht, The Netherlands.
出版信息
Biol Psychiatry. 1996 Nov 1;40(9):913-7. doi: 10.1016/0006-3223(95)00494-7.
A group of 20 patients who met the DSM-III-R criteria for panic disorder with or without agoraphobia underwent a 35% carbon dioxide (CO2) challenge after either 1 mg alprazolam or placebo in a double-blind, randomized, cross-over design. Despite the anxiolytic potential of alprazolam, it produced no significant effects on CO2-induced anxiety and panic symptomatology when compared to placebo.
一组符合《精神疾病诊断与统计手册》第三版修订版（DSM-III-R）中伴或不伴广场恐惧症的惊恐障碍标准的20名患者，在双盲、随机、交叉设计中，服用1毫克阿普唑仑或安慰剂后，接受了35%二氧化碳（CO2）激发试验。尽管阿普唑仑具有抗焦虑潜力，但与安慰剂相比，它对CO2诱发的焦虑和惊恐症状没有产生显著影响。
Zotero 插件